å¨è±ç 究è ãã¦ããã¼ã·ãã£ã»ã«ã¬ãã¸ã»ãã³ãã³(UCL)ã§ç 究室ã主宰ãå ç«å¦è ï¼ç®èç§å»ãæ¬ããã°ããã³ãã¤ãã¿ã¼(@masahirono)ã§ã¯ã主ã«è±å½äºæ ãæ¿æ²»ç¤¾ä¼ãªã©ã«ã¤ãã¦ç§è¦ãã¤ã¶ããã¦ãã¾ããç 究ç¨ãã¼ã ãã¼ã¸ã¯ãã¡ã å®ã¯ç¾å¨ã®å ç«å¦ã®ï¼ããã«ã¯å¤ãã®å»å¦çç©å¦ã®ï¼æ¸¬å®ãã¼ã¿ã®æ®ã©ããã¹ãããæ®å½±ãã«ãããªããããã¦æéã®ééã¯ãæ³åã§åãããã¨ã§çè«ãçµã¿ç«ã¦ããã¦ãããããã¯èªæã®ãã¨ã ããã©ããã®åé¡ã®éè¦æ§ã«æ°ãã¤ãã¦ããªã人ãå¤ããå®éãå ç«å¦ã®èª¤è¬¬ã®å¤§ããªåå ã¯ããã«ããã®ã¯ééããªãã®ã ããæ¸ããã¦ããªãã»èãããã¨ããªã話ãæ¸ãã¦ããä½ã®ãã¨ãã¨æãããã®ãé¢ã®å±±ã§ããããã ãããã¡ãã£ã¨ãã®èæ¯ã詳ããæ¸ãã¦ã¿ããã¨æã£ãã ï¼ï¼ã¨ã¬ãã¡ã³ããã³è¨åºè©¦é¨ã¨å¶å¾¡æ§Tç´°è ï¼ï¼ï¼ï¼å¹´ãå¶å¾¡æ§Tç´°èæ¨çå ç«çæ³ãã®è¨åºè©¦é¨ãè¡ãããè±å½ã§ã¯ã試é¨è¬ã§å¤èå¨ä¸å ¨ã«
Biosimilarã®ãã¥ã¼ã¹ãèããªãæ¥ãç¡ããªãã¤ã¤ãããä¸æã¯ã«ãããªã«æççãªã°ãã¼ãã«ã¡ã¬ãèºèºããééã縫ã£ã¦æåãåããVBãåºãããpatent cliffãªã©ã«ããåçæ©ä¼ã®æ¸å°ã§å½¢æ¯ãæ§ããªããªã£ãã°ãã¼ãã«ã¡ã¬ãè»ä¸¦ã¿åå ¥ããããã«ãªã£ã¦å¢åå³ã¯å¤ãã£ã¦æ¥ãããã«æããå æ¥ãEPIRUS BiopharmaceuticalsãRemicadeã®å¾çºåã®Ph3ã§è¯å¥½ãªçµæãçºè¡¨ãããã±ã£ã¨ããªãã http://www.epirusbiopharma.com/news-articles/BOW-015-Positive-P3-Data.html Biologicsã®éã®ï¼ã¤ã§ããAmgenãªã©ãEPOãG-CSF以å¤ã®Biosimilarã¯ãã«ã©ã¤ã³ã¢ããã§éçºããã¦ããããã ããä¸æ¹ã§å è¬ãTevaã¨Lonzaãbio similar VBã解æ¶ãã¦ããããã«ãããã
京é½å¤§å¦ãç©è³ªï¼ç´°èçµ±åã·ã¹ãã æ ç¹ï¼iCeMSï¼ã¢ã¤ã»ã ã¹ï¼åææ æé¨ç§å¦çæè½ã®ç§å¦æè¡æ¿çç 究æãã¾ã¨ãããä»å¾ï¼ï¼å¹´ã®æè¡çºå±ã®ãæªæ¥å°å³ãããä»æï¼ï¼æ¥ã«çºè¡¨ããããããã«ããã°ãiPSç´°èï¼èªå°å¤è½æ§å¹¹ç´°èï¼ã«ããåçå»çãå®ç¾ããã®ã¯2032å¹´ã§ãããç æ¼ ã®ç·åæè¡ãæ®åããã®ã¯2029å¹´ã§ãããã¡ãªã¿ã«æ¬èª¿æ»ã¯ãå調æ»åéã«è©³ãã大å¦ææãæ°éæè¡è ãç´2,900人ã«ããäºæ¸¬ã¨ãããããããããå°é家ã®éã®åæï¼ã³ã³ã»ã³ãµã¹ï¼ã¨ã¿ãªãã¦ããã ããã ããã¦ãå¤ãã®å½æ°ã¯ãããã§ã²ã¨ã¤ã®ç´ æ´ãªçåãæããã«éããªããããªããããªã«æéããããã®ï¼ãã£ã¨æ©ãå®ç¾ããã¨æã£ã¦ãããã©ï¼ãã¨ããçåãã§ããã確ãã«ãå··ã®å ±éã¯ãããããææ¥ã«ã§ãå®ç¾ããããªé¢¨æ½®ã§ããã ãã¨ãã°ãæ¬å¹´7æ7æ¥ã®æ¯æ¥æ°èæåã«è¨è¼ãããããé ä¿¡ãããã以ä¸ã®è¨äºãè¦ã¦ã¿ããã iPSç´°èã§å®å ¨ã«ã
ã¡ã³ããã³ã¹
ãç¥ãã
é害
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}